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Background: The use of dermoscopy improves the diagnosis of skin cancer significantly in trained 
dermatologists. However, to evaluate its cost-effectiveness in daily practice, not only sensitivity but 
also the excision rate is important.
Objective: We examined the diagnostic accuracy of cases from a true population-based sample scored 
by general dermatologists.
Methods: One hundred twenty-six dermatologists were randomly assigned to 145 digital cases of 
lesions detected at a skin cancer screening. This resulted in 4,655 case evaluations using a web appli-
cation. Accuracy of diagnosis and treatment was correlated with the histological diagnosis or expert 
opinion.
Results: The larger portion (89.7%) of the participating dermatologists reported using their derma-
toscope daily. The odds of making a correct diagnosis of melanoma using dermoscopy was 5.38 com-
pared with naked-eye examination (NEE). Dermoscopy increased sensitivity for skin cancer diagnosis 
from 70.6% to 84.6%, but this was associated with a small but significant decrease in specificity 
of  3.5%. To detect  1  skin cancer, 5.23  lesions had to be biopsied/excised in this sample and this 
was not significantly improved by dermoscopic evaluation. Dermoscopy significantly increased the 
confidence about making a correct diagnosis, especially in seborrheic keratosis, Bowen disease, and 
melanoma.
Conclusions: Dermoscopy significantly improved diagnostic accuracy, the sensitivity of skin cancer 
detection, and the confidence in diagnosis especially for seborrheic keratosis, Bowen disease, and 
melanoma. However, this finding was not reflected in a significant reduction in the number needed to 
excise in this sample.
ABSTRACT
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cal or dermoscopy image. This study was approved by the 
Flemish government and by the medical ethical committee 
of the University Hospital Ghent. All screenees provided 
written informed consent.
As a histological diagnosis was not available for most of 
the lesions, the following surrogate reference diagnosis was 
used in a hierarchical order: diagnosis of the pathologist in 
case of excision or biopsy of the lesion (n = 5; 3.4%), con-
cordant diagnosis by 2 blinded expert dermoscopists (K.V., 
L. B. [n = 100; 68.5%]); in case of discordance in diagnosis 
by these 2 experts, a third independent and blinded expert 
dermoscopist (G.A.) was asked and the most concordant 
diagnosis was chosen (n = 41; 28.1%). The gold standard 
diagnoses of all cases are listed in Table 1.
Recruitment of Dermatologists
A personal invitation to participate in this study was sent 
to all 384 Flemish certified dermatologists. One hundred 
twenty-six (32.8%) dermatologists were included in the study. 
Participants were asked to register online and to evaluate 1 or 
more series of 25 cases each. Case series were presented ran-
domly to each registered dermatologist. Upon registration, 
general information concerning their practice, previous train-
ing in dermoscopy, and the frequency of use of dermoscopy 
in routine practice was elicited.
Case Evaluation
Each online case mentioned brief clinical information (age, 
gender, and location of the lesion). First dermatologists were 
Introduction
The skin cancer epidemic has an important impact on health 
care budget. Early detection and treatment is assumed to give 
better cure rates and subsequently a more cost-effective treat-
ment. Dermoscopy is a well-established technique for diag-
nosis of melanoma and nonmelanoma skin cancer. Several 
meta-analyses have shown that dermoscopy, in the hands of 
experienced dermatologists, is superior to naked-eye exami-
nation (NEE) to detect melanoma [1-3]. Dermoscopy also sig-
nificantly increases the diagnostic accuracy of nonmelanoma 
skin cancer diagnosis [4]. For basal cell carcinoma (BCC) the 
dermoscopic diagnostic accuracy is up to 95%-99% [5-7]. 
It is known that the diagnostic accuracy of dermoscopy 
depends significantly on training of the examiners [8]. In 
the hands of untrained practitioners, dermoscopy provides 
no better diagnostic accuracy for melanoma than NEE [1]. 
Most of the studies on the additional diagnostic value of 
dermoscopy have been performed in a well-selected set of 
lesions, in which melanomas and other malignant lesions 
are usually overrepresented. Since skin cancer prevalence in 
real-life setting is usually much lower, this can influence the 
number of false-positive diagnoses and their related cost in 
an important way (Bayes’ theorem). For this reason we exam-
ined diagnostic accuracy and treatment allocation by NEE 
alone and additional dermoscopy among dermatologists in a 
population-based screening sample in Belgium.
Methods
Study Design
Cases and Determination of Reference Diagnosis
The cases were collected during a population-based lesion-
directed skin cancer screening. Screenees could register for 
a free-of-charge skin cancer check-up if they had a lesion 
meeting 1 or more of the following criteria: ABCD rule, ugly 
duckling sign, a new lesion lasting more than 4 weeks, or 
red nonhealing lesions. All the index lesions presented by 
the screenees were checked and photographed both clini-
cally and dermoscopically, respectively with an EOS 1200 D 
camera (Canon, Giessen, Germany) and the DermLite Photo 
System (3Gen, San Juan Capistrano, CA, USA). Follow-
ing this lesion- directed screening, a total body check was 
offered to all participants for ethical reasons. We did not 
photograph any lesions during this second phase of the 
screening. In total 248 lesions were screened and 8 of them 
were histologically proven to be skin cancers (3.2%). Fur-
ther details on this screening initiative have been published 
elsewhere [9]. In total 145 of the 248 cases (58%) were 
selected for a web application. Exclusion of cases was due 
to suboptimal quality of the photographs or a missing clini-
Table 1. Specific Diagnoses of Lesions in the 145 
Cases
No. %
Diagnosis
 Melanoma 1 0.69
 BCC 4 2.76
 SCC/Bowen 1 0.69
 Actinic keratosis 3 2.07
 Angioma 5 3.45
 Dermatofibroma 4 2.76
 Atypical nevus 6 4.14
 Blue nevus 3 2.07
 Congenital nevus 6 4.14
 Benign nevus 53 36.55
 Solar lentigo 12 8.27
 Seborrheic keratosis 40 27.69
 Other 7 4.82
Total 145 100
SCC = squamous cell carcinoma.
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shown the clinical picture and were asked to select a clinical 
diagnosis (multiple choice), to score the certainty of their 
diagnosis on a visual analogue scale from 0 to 100%, and 
to choose the best treatment action (no treatment, biopsy, 
surgical excision, curettage, cryotherapy, and other); after reg-
istration of these answers they were shown the dermoscopy 
photograph and were asked to complete the same questions.
Sample Size Calculation and Statistical Analysis
A sample size of 1,630 case evaluations was required to 
achieve a power of 80% to detect a difference in specific-
ity of 5% in the group of clinical evaluation compared 
with the group of additional dermoscopy evaluation with 
a significance level of 5%. A specificity of 85.4% for the 
clinical diagnosis was expected and an interclass correlation 
of 0.814 was assumed (based on pilot data). Sample size cal-
culation was adjusted for the clustered nature of the design by 
applying the method described by Killip et al [10]. Descriptive 
statistics were used to describe the cases and dermatologists 
participating. The related samples Wilcoxon signed rank test 
was used for continuous variables. Because of the clustered 
nature of the data, mixed logistic regression models were 
used to calculate sensitivity, specificity, and number needed 
to excise (NNE) and their relation to experience and training 
of the dermatologist. All statistical tests were 2-tailed and P 
values <0.05 were considered statistically significant. The 
analyses were conducted in SPSS version 21.0 (IBM, Armonk, 
NY, USA).
Outcomes
The primary outcome of this study was to evaluate the 
diagnostic accuracy of dermoscopy compared with NEE 
in a population-based setting. Furthermore, we wanted to 
evaluate whether dermoscopy can increase certainty of the 
correct diagnosis.
Results
Participant Characteristics
In total 126 dermatologists randomly evaluated 1 or more 
series of cases with a mean of 32.1 evaluations per case. 
This resulted in 4,655 case evaluations; 80.2% of the par-
ticipants were female and 19.8% were male. The median age 
was 45 years (interquartile range [IQR]: 38-52). The major-
ity of dermatologists worked in a private practice (54.8%), 
38.9% in a university center and 6.3% in a hospital setting. 
The reported median number of patients seen in routine 
practice was 100 per week (IQR: 70-130). Dermoscopy was 
used at least once a day in 89.7%, once a week but not daily 
in 7.9%, once a week up to once a month in 1.6%, and not 
at all in 0.8%. Thirty-seven (29.4%) used a nonpolarized 
dermatosope. Training in dermoscopy varied among par-
ticipants: only 3 dermatologists (2.4%) had no training in 
dermoscopy, whereas 25 (19.8%) had 1-5 hours, 42 (33.3%) 
had 5-10 hours, and 44.4% had more than 10 hours of 
training.
Diagnostic Accuracy and Certainty of Diagnosis
Dermoscopy increased sensitivity for skin cancer diagnosis 
significantly from 70.6% to 84.6% (binomial generalized 
linear mixed model, P = 0.002; Table 2), associated with a 
small but significant decrease in specificity (96.9% for NEE 
vs 93.5% for dermoscopy, binomial generalized linear mixed 
model, P < 0.001; Figure 1). The sensitivity for the diagnosis 
Table 2. Diagnostic Performance of Dermoscopy According to Level of Training of the Dermatologist
Clinical Dermoscopy
Sens Spec 1 − Spec Sens Spec 1 − Spec
All 0.706 
(0.625-0.775)*
0.969 
(0.959-0.977)**
0.031 0.846 
(0.781-0.894)
0.935 
(0.915-0.950)**
0.065
Training 
 < 5 hrs 0.645 
(0.461-0.795)1
0.915 
(0.886-0.938)2
0.085 0.774 
(0.593-0.890)3
0.861 
(0.810-0.900)4
0.139
 5-10 hrs 0.702 
(0.588-0.796)1
0.921 
(0.903-0.935)2
0.079 0.829 
(0.726-0.899)3
0.885 
(0.854-0.910)4
0.115
 > 10 hrs 0.704 
(0.593-0.795)1
0.940 
(0.927-0.951)2
0.060 0.852 
(0.755-0.915)3
0.887 
(0.861-0.909)4
0.113
Sensitivity and specificity, binomial generalized linear mixed models. 
* P = 0.002 (odds ratio: 0.43 [95% confidence interval: 0.26-0.73]).
** P < 0.001 (OR: 2.18 [95% confidence interval: 1.84-2.58]).
1,2,3,4 P = NS.
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of melanoma with the use of dermoscopy increased even more 
from 76.0% to 94.0% (binomial generalized linear mixed 
model, P = 0.028). The odds for making a correct diagnosis of 
melanoma using dermoscopy was 5.38 (95% CI: 1.22-23.81) 
compared with NEE. Dermoscopy also increased sensitivity 
for diagnosis of BCC and squamous cell carcinoma/Bowen 
from 71.5% to 74.6%, and 58.9% to 71.0%, respectively, 
but this failed to reach statistical significance.
A trend to increasing sensitivity/specificity was observed 
with increasing training level (Figure 2). The confidence about 
a correct diagnosis significantly increased from a median 
of 70% (IQR: 60-80) using NEE to 83.7% (IQR: 70-90) with 
dermoscopy (related samples Wilcoxon signed rank test (P < 
0.001)). This increase was most pronounced for seborrheic 
keratosis, Bowen disease, and melanoma (Figure 3).
Number Needed to Excise
Dermoscopy resulted in 43 additional excisions for skin 
cancer and 252 extra excisions for benign lesions (on a total 
of 1,675 excisions or biopsies performed) compared with 
the clinical evaluation without dermoscopy. This resulted in 
a NNE of 4.77 for clinical evaluation alone and 5.23 when 
using dermoscopy (binomial generalized linear mixed model, 
P = not significant [NS]). The NNE did not seem to be influ-
enced by training level (0-5 hours, NNE 5.15; 5-10 hours, 
NNE 4.89; and >10 hours, NNE 5.62; binomial generalized 
linear mixed model, P = NS; Table 3). Also for specific sub-
categories of lesions (melanocytic lesions and BCC) the NNE 
did not change significantly between clinical diagnosis and 
dermoscopy diagnosis (Table 3).
Figure  1. Sensitivity and 1  minus specificity for a 
malignant diagnosis made clinically and using der-
moscopy. Dermoscopy increased sensitivity for skin 
cancer diagnosis significantly from 70.6% to 84.6% 
(binomial generalized linear mixed model, P = 0.002), 
associated with a small but significant decrease in 
specificity (96.9% for NEE vs 93.5% for dermoscopy, 
binomial generalized linear mixed model, P < 0.001). 
[Copyright: ©2019 Hoorens et al.]
Figure  2. Sensitivity and  1  minus specificity for a 
malignant diagnosis according to level of training of 
the dermatologist. Sensitivity and specificity for skin 
cancer diagnosis increased with advanced level of 
training, although this failed to reach statistical sig-
nificance (binomial generalized linear mixed model, 
P = NS). [Copyright: ©2019 Hoorens et al.]
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Discussion
In this study the additional value of dermoscopy over NEE 
diagnosis by 126 dermatologists was evaluated in a popu-
lation-based series of 145 cases. In the past many similar 
studies have used very selected case series in which skin 
cancer was usually overrepresented. Although the intention 
is not to miss any skin cancer (100% sensitivity), especially in 
melanoma, the importance of not overdiagnosing skin cancer 
(high specificity) may also be an important issue to avoid 
the individual (fear, unnecessary intervention) and societal 
(cost) disadvantages of false-positive diagnoses. In non–high-
risk populations the specificity will have a higher impact 
on cost-effectiveness. In this study we therefore included a 
case series based on a population-based lesion-directed skin 
cancer screening program, in which skin cancer prevalence 
was only 6/145 (4.1%). Nearly one third of all Flemish 
dermatologists evaluated at least 25 of the 145 cases. Cases 
were randomly presented to the participants, leading to a 
total of 4,655 case evaluations. In this way this study reflects 
the additional value of dermoscopy in the hands of general 
dermatologists in a population-based setting.
The results of this study demonstrate that dermoscopy is 
frequently used in Belgian dermatology practice: almost 90% 
of participants use their dermatoscope daily. This is compa-
rable with large studies performed in France and Australia 
(94.6%-98%) [11,12].
In accordance with other studies, we observed that der-
moscopy significantly increases sensitivity for malignant 
lesions [1-4,6]. However, this results also in a small but sig-
nificant decrease in specificity, thus increasing the number of 
false-positive diagnoses. In this study dermoscopy resulted 
in 43 additional excisions for skin cancer and 252 extra 
excisions for benign lesions over clinical diagnosis. The 
sensitivity/specificity tended to increase with increased 
level of training, confirming the results of previous studies 
[1-4,6]. Confidence about making a correct diagnosis was 
significantly higher using dermoscopy, especially in mela-
noma, seborrheic keratosis, and Bowen disease. However, 
this did not result in a reduction of unnecessary excisions as 
the NNE did not significantly differ between clinical diag-
nosis and dermoscopy nor did it seem to be influenced by 
training. Subanalyses with years of dermoscopy experience, 
daily use, in addition to level of training taken into account, 
also could not reveal a significant difference in the NNE. 
However, the NNE of the experts in the real-life setting on 
the screening (K.V., L.B.) was clearly lower than the NNE 
reached in the online case evaluation (ie, NNE 1.25 in real-
life screening) [9].
The use of both clinical and dermoscopic photographs 
with the added information of gender, age, and lesion loca-
tion to evaluate pigmented skin lesions remains somewhat 
artificial. In the absence of a total body inspection, individual 
lesions may be interpreted in a different way. An individual 
with multiple nevi, for instance, usually displays similar 
lesions (signature nevi); on the other hand there should be 
caution about lesions with a different pattern (ugly duckling 
sign). This was illustrated by 2 prominent nevi that were 
considered nonsuspicious by the 2 experts (K.V., L.B.) on 
the screening and were scored as potential melanoma in the 
online case series by at least 2 of 3 experts (G.A., K.V., L.B.). 
Digital follow-up of these lesions by means of new clinical 
and dermoscopy photographs about 20 months after screen-
Figure 3. Median certainty of diagnosis clinically vs dermoscopy per diagnostic group. Certainty diagnosis median on visual analogue scale 
from 0 to 100%. AK = actinic keratosis; VS = seborrheic keratosis. [Copyright: ©2019 Hoorens et al.]
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ing showed no change, hence suggesting that these lesions 
have a benign behavior. This finding illustrates that some of 
the false-positive skin cancer diagnoses may have been due to 
the artificial conditions in which these lesions were evaluated.
Compared with previous studies, a NNE of 1 out of 6 was 
obtained in this study. Evaluation of the large SCREEN cam-
paign in Germany in a partially nonspecialized setting not 
using dermoscopy resulted in 17 excisions of melanocytic 
lesions for the detection of 1 melanoma [13]. Our data are 
comparable with those of a large multicentric study examin-
ing excision rates over a period of 10 years in specialized 
clinical settings, with a NNE of 6.8 [14].
Table 3. NNE Dermoscopy vs Clinical Situation According to Level of Training
All Lesions
Level of 
Training
Excision/Biopsy 
Malignant
Excision/Biopsy 
Benign
Total Excisions 
(NNE)
Method 
 Clinical 
<5 hrs 31 100 131 (4.22)
5-10 hrs 58 230 288 (4.96)
 >10 hrs 61 235 296 (4.85)
  Total 150 565 715 (4.77)*
 Dermoscopy 
<5 hrs 33 137 170 (5.15)
5-10 hrs 81 315 396 (4.89)
>10 hrs 79 365 444 (5.62)
  Total 193 817 1010 (5.23)*
Melanocytic 
Lesions
Level of 
Training
Excision/Biopsy 
Malignant
Excision/Biopsy 
Benign
Total Excisions 
(NNE)
Method 
 Clinical 
<5 hrs 14 51 65 (4.57)
5-10 hrs 22 126 148 (6.73)
 >10 hrs 29 136 165 (5.69)
  Total 65 313 378 (5.81)*
 Dermoscopy 
<5 hrs 15 79 94 (6.26)
5-10 hrs 36 195 231 (6.41)
>10 hrs 43 240 283 (6.58)
  Total 94 514 608 (6.46)* 
BCC
Level of 
Training
Excision/Biopsy 
Malignant
Excision/Biopsy 
Benign
Total Excisions 
(NNE)
Method 
 Clinical 
<5 hrs 10 32 42 (4.20)
5-10 hrs 18 71 89 (4.94)
 >10 hrs 17 54 71 (4.18)
  Total 45 157 202 (4.49)*
 Dermoscopy 
<5 hrs 13 28 41 (3.15)
5-10 hours 27 62 89 (3.30)
>10 hrs 20 47 67 (3.35)
  Total 60 137 197 (3.28)*
NNE to find 1 confirmed skin cancer, melanoma, or BCC, binomial generalized linear mixed models.
*P = NS.
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There was a trend toward increased sensitivity and speci-
ficity with increased training; however, training of >10 hours 
did not reach statistically significant superior results. In the 
recent NICE guidelines it is recognized that dermoscopy is 
unequivocally useful in the diagnosis of melanoma, but only 
in the hands of trained users [15]. The required amount of 
training, however, is a topic of debate. It has been shown 
that despite the frequent use of dermoscopy, training seems 
to be insufficient and that even among dermatologists who 
consider themselves experienced in dermoscopy, repeated 
training can increase diagnostic accuracy [8,11]. In addition, 
currently a lot of training courses in dermoscopy mainly focus 
on red flags (increased sensitivity for melanoma). However, 
when used in low-prevalence populations, it could be interest-
ing to put more focus on green flags (recognition of harmless 
lesions), thereby reducing the number of false-positive diag-
noses and hence unnecessary excisions.
Conclusions
The current study evaluated the additional value of dermos-
copy in the hands of general dermatologists in a population-
based setting using a series of photos in a web application. 
These results demonstrate that dermoscopy clearly increases 
sensitivity for malignant lesions in a population-based setting 
at the expense of a small but significant decrease in specific-
ity. Although dermoscopy significantly increased confidence 
about a diagnosis, especially in melanoma, seborrheic kera-
tosis and Bowen disease, this did not result in a reduction 
of NNE. There was a trend toward higher sensitivity and 
specificity according to training level (<5 hours, 5-10 hours, 
or >10 hours). We suggest that continuous training for der-
moscopy is necessary and that training courses should also 
pay enough attention to the recognition of benign lesions to 
avoid unnecessary excisions and in that way benefit cost-
effectiveness ratios.
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